The 30 references in paper P. Rumyantsev O., D. Fomin K., U. Rumyantseva V., П. Румянцев О., Д. Фомин К., У. Румянцева В. (2015) “КРИТЕРИИ РЕЗИСТЕНТНОСТИ ВЫСОКОДИФФЕРЕНЦИРОВАННОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ К ТЕРАПИИ РАДИОАКТИВНЫМ ЙОДОМ // CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY” / spz:neicon:ogsh:y:2014:i:3:p:4-9

1
Румянцев П. О., Ильин А. А., Румянцева У. В., Саенко В. А. Рак щитовидной железы. Современные подходы к диагностике и лечению. М.: ГЭОТАР-Медиа, 2009. 448 с.
(check this in PDF content)
2
Cisco R. M., Shen W. T., Gosnell J. E. Extent of surgery for papillary thyroid cancer: preoperative imaging and role of prophylactic and therapeutic neck dissection. Curr Treat Options Oncol 2012;13(1):1–10.
(check this in PDF content)
3
Pacini F., Schlumberger M., Dralle H. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154(6):787–803.
(check this in PDF content)
4
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper D. S., Doherty G. M., Haugen B. R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214.
(check this in PDF content)
5
Румянцев П. О., Коренев С. В., Румянцева У. В. Современные принципы терапии левотироксином после операции у больных высокодифференцированным раком щитовидной железы. Опухоли головы и шеи 2013;(2):5–8.
(check this in PDF content)
6
Eustatia-Rutten C. F., Corssmit E. P., Biermasz N. R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9.
(check this in PDF content)
7
Jonklaas J., Sarlis N. J., Litofsky D. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16(12):1229–42.
(check this in PDF content)
8
Vrachimis A., Schober O., Riemann B. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation. Nuklearmedizin 2012;51(3):67–72.
(check this in PDF content)
9
Солодкий В. А., Фомин Д. К., Подольхова Н. В. и др. Радионуклидная терапия у больных дифференцированным раком щитовидной железы группы низкого риска прогрессирования. Вестник РНЦ рентгенорадиологии МЗ РФ 2012, http:// vestnik.rncrr.ru / vestnik / v12 / papers / fomin_ v12.htm.
(check this in PDF content)
10
Spitzweg C., Bible K. C., Hofbauer L. C., Morris J. C. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol 2014 May 30.
(check this in PDF content)
11
Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9.
(check this in PDF content)
12
Sabra M. M., Grewal R. K., Tala H. et al. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. Thyroid 2012;22(9):877–83.
(check this in PDF content)
13
Sgouros G., Kolbert K. S., Sheikh A. et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004;45(8):1366–72.
(check this in PDF content)
14
Robbins R. J., Wan Q., Grewal R. K. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxyD-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91(2):498–505.
(check this in PDF content)
15
Leboulleux S., El Bez I., Borget I. et al. Post-Radioiodine Treatment Whole Body Scan in the Era of Fluorodesoxyglucose Positron Emission Tomography for Differentiated Thyroid Carcinoma with elevated serum thyroglobulin levels. Thyroid 2012 Jun 5.
(check this in PDF content)
16
Vaisman F., Tala H., Grewal R., Tuttle R. M. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 2011;21(12):1317–22.
(check this in PDF content)
17
Pacini F. Where do we stand with targeted therapy of refractory thyroid cancer? – Utility of RECIST criteria. Thyroid 2008;18(3):279–80.
(check this in PDF content)
18
Schlumberger M., Brose M., Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014;2(5):356–8.
(check this in PDF content)
19
Shimaoka K., Schoenfeld D. A., DeWys W.D. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56(9):2155–60.
(check this in PDF content)
20
Droz J. P., Schlumberger M., Rougier P. et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990;76(5):480–3.
(check this in PDF content)
21
Kloos R. T. Papillary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 2005;6(4):323–38.
(check this in PDF content)
22
Riesco-Eizaguirre G., Rodriguez I., De la Vieja A. et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 2009;69(21):8317–25.
(check this in PDF content)
23
Gao W. L., Wie L. L., Chao Y. G. et al. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas. Clin Lab 2012;58(9–10):919–26. ли менее 1 см в диаметре без признаков прогрессирования последних должны активно наблюдаться [29]. Международная группа экспертов считает, что если один или более метастатических очагов ВДРЩЖ перестают накапливать радиоактивный йод и прогрессируют в размерах, то пациент считается радиойодрезистентным, лечение радиоактивным йодом необходимо прекратить и начинать таргетную системную терапию потенциально эффективным мультикиназным ингибитором [18]. Резюмируя вышеизложенное, ВДРЩЖ следует считать радиойодрезистентным при наличии одного или не
(check this in PDF content)
24
Yang K., Wang H., Liang Z. et al. BRAFV600E mutation associated with nonradioiodine-avid status in distant metastatic papillary thyroid carcinoma. Clin Nucl Med 2014;39(8):675–9.
(check this in PDF content)
25
Sabra M. M., Dominguez J. M., Grewal R. K. et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab 2013;98(5):E829–36.
(check this in PDF content)
26
D’Agostino M., Sponziello M., Puppin C. et al. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. J Mol Endocrinol 2014;52(2):121–31.
(check this in PDF content)
27
Ho A. L., Grewal R. K., Leboeuf R. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013;368(7):623–32.
(check this in PDF content)
28
Rothenberg S. M., McFadden D.S., Palmer E. et al. Re-differentiation of radioiodine-refractory BRAF V600E-mutant thryoid carcinoma with dabrafenib: a pilot study. J Clin Oncol (ASCO Meeting Abstracts) 2013;31:6023.
(check this in PDF content)
29
Xing M., Haugen B. R., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381(9871):1058–69.
(check this in PDF content)
30
Sacks W., Braunstein G. D. Evolving approaches in managing radioactive iodinerefractory differentiated thyroid cancer. Endocr Pract 2014;20(3):263–75.
(check this in PDF content)